Advertisement

Fetal Pharmacology and Therapy

  • E. Jacqz Aigrain
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 25)

Abstract

Major progresses have been made in recent years in investigating fetal disorders. Echography now allows precise diagnosis of congenital malformations (such as digestive, urinary tract or cardiac abnormalities). Diagnosis of abnormal karyotype is possible with chorion biopsy, amniocentesis or fetal blood sampling. Such procedures have their own complications but their frequency is reduced in experienced hands. The therapeutic decision of whether to carry on pregnancy and to treat fetal diseases or to induce abortion is obviously a matter of individual cases and differences in legislation in various countries.

Keywords

Congenital Adrenal Hyperplasia Congenital Hypothyroidism Congenital Toxoplasmosis Fetal Growth Retardation Fetal Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ward RM (1995) Pharmacological treatment of the fetus. Clinical pharmacokinetic considerations. Clin Pharmacokinet 28:343–350.PubMedCrossRefGoogle Scholar
  2. 2.
    Pacifici GM, Nottoli R (1995) Placental transfer of drugs administered to mothers. Clin Pharmacokinet 28:235–269.PubMedCrossRefGoogle Scholar
  3. 3.
    Levy G (1981) Pharmacokinetics of fetal and neonatal exposure to drugs. Obstet Gynecol 58:9S-16S.PubMedGoogle Scholar
  4. 4.
    Azancot Benisty A, Jacqz Aigrain E, Guirgis NM, De Crepy A, Oury JF, Blot P (1992) Clinical and pharmacological study of fetal supraventricular tachyarrhythmias. J Pediatr 121:608–613.CrossRefGoogle Scholar
  5. 5.
    Maxwell DJ, Crawford DC, Curry PVM, Tynan MJ, Allan LD (1988) Obstetric importance, diagnosis and management of fetal tachycardias. BMJ 297:107–110.PubMedCrossRefGoogle Scholar
  6. 6.
    VanEngelen AD, Weijtens O, Brenner JI, Kleinman CS, Copel JA, Stoutenbeek P, Meijboom EJ (1994) Management outcome and follow-up of fetal tachycardia. J Am Coll Cardiol 24:1371–1375.PubMedCrossRefGoogle Scholar
  7. 7.
    Dupouy Carnet J, Gavinet MF, Paugam A, Tourte-Schaefer C (1993) Mode de contamination, incidence et prevalence de la toxoplasmose. Med Mai Inf 23:139–147.CrossRefGoogle Scholar
  8. 8.
    Wong SY, Remington JS (1994) Toxoplasmosis during pregnancy. Clin Infect Dis 18:853–862.PubMedCrossRefGoogle Scholar
  9. 9.
    Hohfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M (1994) Prenatal diagnosis of congenital toxoplasmosis with a polymerase chain reaction test on amniotic fluid. N Eng J Med 331:695–699.CrossRefGoogle Scholar
  10. 10.
    Wilson CB (1990) Treatment of congenital toxoplasmosis during pregnancy. J Pediatr 116:1003–1004.PubMedGoogle Scholar
  11. 11.
    Couvreur J, Desmonts G, Thulliez P (1988) Prophylaxis of congenital toxoplasmosis: effects of spiramycin on placental infection. J Antimicrob Chemother 22:193–200.PubMedCrossRefGoogle Scholar
  12. 12.
    Hohfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, Descombey D, Forestier F (1989) Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 115:765–769.CrossRefGoogle Scholar
  13. 13.
    Morel Y, Miller WL (1991) Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv Hum Genet 20:1–68.PubMedGoogle Scholar
  14. 14.
    Forest MG, David M, Morel Y (1993) Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 45:75–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Forest MG, Dorr HG (1993) Prenatal treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: European experience in 223 pregnancies at risk. Pediatr Res 33:S3.CrossRefGoogle Scholar
  16. 16.
    Burrow GN, Fisher DA, Larsen PR (1994) Maternal and thyroid function. N Engl J Med 331:1072–1078.PubMedCrossRefGoogle Scholar
  17. 17.
    Perelman AH, Johnson RL, Clemons RD, Finberg HJ, Clewell WH, Trujillo L (1990) Intrauterine diagnosis and treatment of fetal goitrous hypothyroidism. J Clin Endocrinol Metab 71:618–621.PubMedCrossRefGoogle Scholar
  18. 18.
    Friedman SA (1988) Pre-eclampsia: a review of the role of prostaglandins. Obstet Gynecol 71:1.Google Scholar
  19. 19.
    Schiff E, Peleg E (1989) The use of aspirin to prevent pregnancy induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 321:351–356.PubMedCrossRefGoogle Scholar
  20. 20.
    Uzan S, Beaufils M (1989) Idiopathic recurrent fetal growth retardation and aspirin-dipy- ridamole therapy. Am J Obstet Gynecol 160:763–764.PubMedGoogle Scholar
  21. 21.
    Wallenburgh HCS, Rotmans N (1987) Prevention of recurrent idiopathic fetal growth retardation by low dose aspirin and dipyridamole. Am J Obstet Gynecol 157:1230–1235.Google Scholar
  22. 22.
    Spielberg SP, Strickler SM, Miller MA, Andermann E, Dansky LV, Seni MH (1985) Genetic predisposition to phenytoin-induced birth defects. Lancet pp: 746.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • E. Jacqz Aigrain

There are no affiliations available

Personalised recommendations